(Q40167169)

18 September 2017

Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy (English)

1 reference

18 September 2017

1 reference

Lynsey A McHugh

1

1 reference

18 September 2017

Marina Kriajevska

series ordinal

2

1 reference

18 September 2017

John K Mellon

series ordinal

3

1 reference

18 September 2017

Thomas R Griffiths

series ordinal

4

1 reference

18 September 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

18 September 2017

1 reference

18 September 2017

69

1 reference

18 September 2017

390-394

1 reference

18 September 2017

2

1 reference

Global cancer statistics, 2002

18 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.003

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.003

Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.003

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.003

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.003

Untangling the ErbB signalling network

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.003

Ligand-induced, receptor-mediated dimerization and activation of EGF receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.003

Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.003

Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.003

Original Articles: Bladder Cancer: Long-Term Outcome Related to Epidermal Growth Factor Receptor Status in Bladder Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.003

HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.003

Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.003

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.003

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.003

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.003

Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.003

Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.003

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.003

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.003

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.003

Characterization of sequence-dependent synergy between ZD1839 ("Iressa") and oxaliplatin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.003

The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.003

Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.003

Serum predominantly activates MAPK and akt kinases in EGFR- and ErbB2-over-expressing cells, respectively

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.003

10.1016/J.UROLOGY.2006.12.003

7 January 2021

Identifiers

DOI

1 reference

18 September 2017

1 reference